BillionToOne, Inc. (BLLN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Are Medical Stocks Lagging BillionToOne, Inc. (BLLN) This Year?
Here is how BillionToOne (BLLN) and Concentra Group (CON) have performed compared to their sector so far this year.
Baron Health Care Fund Q1 2026 Portfolio Activity
During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.
Does BillionToOne (BLLN) Have the Potential to Rally 37% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 37% in BillionToOne (BLLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BillionToOne, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 180 | $14,209.2 | $23,455.8 | $9,246.6 | 65.07% |
 George Soros Soros Fund Management LLC | 14,500 | $1.19M | $1.89M | $702,815 | 59.23% |
| NM Nir Messafi Deep Track Capita LLP | 50,000 | $4.09M | $6.52M | $2.42M | 59.23% |
 Benj Foor Frazier Financial Advisors, LLC | 14 | $1,146 | $1,792.49 | $646.49 | 56.41% |
| SAM Smartleaf Asset Management LLC Smartleaf Asset Management LLC | 1,297 | $108,166.58 | $166,003.03 | $57,836.45 | 53.47% |
BillionToOne, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mark Massaro BTIG | 18.51 | $1,708.54 | $2,403.75 | $695.21 | 40.69% |
BillionToOne, Inc. (BLLN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BillionToOne, Inc. ever had a stock split?
BillionToOne, Inc. Profile
| Professional Services Industry | Industrials Sector | Oguzhan Atay CEO | NASDAQ (NGS) Exchange | 090168105 CUSIP |
| US Country | 713 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BillionToOne, Inc. is a precision diagnostics company that specializes in quantifying biological elements to develop advanced molecular diagnostics. By utilizing a molecular counting platform, the company aims to detect and measure DNA molecules at the single-count level, which significantly enhances the ability to detect diseases. Founded in 2016 and headquartered in Menlo Park, California, BillionToOne is engaged in pioneering efforts to improve proactive healthcare solutions through innovative testing methods.
Products and Services
- UNITY Complete: This is a non-invasive prenatal screening test that evaluates the risk of fetal aneuploidies, recessive conditions, and fetal antigens. The test requires only a maternal blood draw for assessment, making it an accessible option for expectant mothers seeking crucial information about their pregnancy.
- Northstar Select: A liquid biopsy test designed specifically for oncology applications. This test identifies mutations present in the tumor by analyzing circulating tumor DNA (ctDNA). It encompasses a variety of mutations, including deletions, insertions, and point mutations, which helps clinicians tailor treatment strategies based on the genetic profile of an individual's tumor.
- Northstar Response: This test provides longitudinal assessment of cancer burden by evaluating methylation patterns in cfDNA (circulating free DNA). By determining changes over time, healthcare providers can monitor the effectiveness of treatments and make informed decisions on patient care.
